[go: up one dir, main page]

SV2011003915A - Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia - Google Patents

Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia

Info

Publication number
SV2011003915A
SV2011003915A SV2011003915A SV2011003915A SV2011003915A SV 2011003915 A SV2011003915 A SV 2011003915A SV 2011003915 A SV2011003915 A SV 2011003915A SV 2011003915 A SV2011003915 A SV 2011003915A SV 2011003915 A SV2011003915 A SV 2011003915A
Authority
SV
El Salvador
Prior art keywords
trombocitopenia
thrombocitopenia
reducing
mortality associated
risk
Prior art date
Application number
SV2011003915A
Other languages
English (en)
Inventor
Marco Valgimigli
Original Assignee
Iroko Cardio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42198725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2011003915(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iroko Cardio Llc filed Critical Iroko Cardio Llc
Publication of SV2011003915A publication Critical patent/SV2011003915A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE DESCRIBEN MÉTODOS PARA REDUCIR EL RIESGO DE MORTALIDAD Y MORBILIDAD ASOCIADAS A TROMBOCITOPENIA Y PARA REDUCIR EL RIESGO DE TROMBOCITOPENIA EN PACIENTES CUYO TRATAMIENTO REQUIERE INHIBICIÓN DE LA AGREGACIÓN PLAQUETARIA. LOS MÉTODOS INVOLUCRAN LA ADMINISTRACIÓN DE UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE TIROFIBÁN
SV2011003915A 2008-11-21 2011-05-23 Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia SV2011003915A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11697608P 2008-11-21 2008-11-21

Publications (1)

Publication Number Publication Date
SV2011003915A true SV2011003915A (es) 2011-07-01

Family

ID=42198725

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011003915A SV2011003915A (es) 2008-11-21 2011-05-23 Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia

Country Status (18)

Country Link
US (1) US20120059036A1 (es)
EP (1) EP2355824A4 (es)
KR (1) KR20110108330A (es)
AU (1) AU2009318101A1 (es)
BR (1) BRPI0920984A2 (es)
CL (1) CL2011001175A1 (es)
CO (1) CO6390039A2 (es)
CR (1) CR20110271A (es)
DO (1) DOP2011000149A (es)
EC (1) ECSP11011152A (es)
MA (1) MA32820B1 (es)
MX (1) MX2011005376A (es)
NI (1) NI201100101A (es)
PE (1) PE20110946A1 (es)
SV (1) SV2011003915A (es)
TN (1) TN2011000256A1 (es)
WO (1) WO2010059244A2 (es)
ZA (1) ZA201103741B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101996880B1 (ko) 2018-03-16 2019-07-05 경성대학교 산학협력단 컴파운드 k를 유효성분으로 포함하는 혈소판 감소증 예방 또는 치료용 조성물
CN112441962A (zh) * 2019-09-04 2021-03-05 武汉武药科技有限公司 替罗非班及其纯化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
KR20040025890A (ko) * 2001-01-26 2004-03-26 쉐링 코포레이션 혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와 혈액조절제의 조합물
US6770660B2 (en) * 2002-05-06 2004-08-03 Artery Llc Method for inhibiting platelet aggregation
EP1396269A1 (en) * 2002-09-09 2004-03-10 Trigen Limited Boronic acid salts of multivalent metals used in the preparation of a medicament for treating thrombosis
DE602005019874D1 (de) * 2004-05-12 2010-04-22 Bristol Myers Squibb Co Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1-rezeptors
KR20070091607A (ko) * 2004-10-12 2007-09-11 디코드 제네틱스, 아이엔씨. 폐쇄성 동맥 질환용의 설폰아미드 주변 치환된바이사이클릭 화합물

Also Published As

Publication number Publication date
WO2010059244A3 (en) 2010-10-14
EP2355824A4 (en) 2012-11-07
KR20110108330A (ko) 2011-10-05
US20120059036A1 (en) 2012-03-08
CO6390039A2 (es) 2012-02-29
TN2011000256A1 (en) 2012-12-17
ECSP11011152A (es) 2011-09-30
NI201100101A (es) 2011-12-19
CL2011001175A1 (es) 2011-11-11
EP2355824A2 (en) 2011-08-17
AU2009318101A1 (en) 2010-05-27
BRPI0920984A2 (pt) 2017-07-11
DOP2011000149A (es) 2011-10-31
PE20110946A1 (es) 2012-01-05
CR20110271A (es) 2011-10-13
MX2011005376A (es) 2011-10-19
WO2010059244A2 (en) 2010-05-27
ZA201103741B (en) 2012-01-25
MA32820B1 (fr) 2011-11-01

Similar Documents

Publication Publication Date Title
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
GT201300234A (es) Sales de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
MX346730B (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
CR20140086A (es) Tratamientos de combinación para hepatitis c
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
MX2016000121A (es) Tratamiento de lesiones inflamatorias de rosacea con invermectina.
CL2013000735A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
MX350719B (es) Composiciones de bakuchiol para el tratamiento de hiperpigmentacion post-inflamatoria.
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
CO2018002534A2 (es) Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
SV2011003915A (es) Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia
UY32507A (es) Una dosis de ave5026 para el tratamiento de trombormbolismo venoso en pacientes con deterioro renal severo
AR076520A1 (es) Parasiticidas sanguineos. composicion
AR094224A1 (es) Composicion farmaceutica en forma de una suspension oral
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.
NI201200196A (es) Agentes terapéuticos 976
UY33431A (es) Sal de tirofibán y uso para reducir la trombacitopenia y mortalidad asociada a la trombocitopenia
AR081639A1 (es) Una sal de tirofiban y uso de una cantidad efectiva de una sal de tirofiban farmaceuticamente aceptable para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia
DOP2014000221A (es) Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek
CL2013003671A1 (es) Composicion y combinacion farmaceutica que comprende ketorolaco y meloxicam; proceso para preparar la composicion; uso en el tratamiento de la inflamacion y el dolor.
MX2015005486A (es) Usos de bremelanotida en terapia para la disfuncion sexual femenina.